Omlyclo (Omalizumab)

Omalizumab, the active ingredient in Omlyclo, is a monoclonal antibody presented as a strength/form for subcutaneous injection use. It targets severe allergic asthma and chronic spontaneous urticaria in patients who remain uncontrolled despite standard therapy. GNH USA supplies Omlyclo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omlyclo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omlyclo is a monoclonal antibody that modulates IgE‑mediated pathways in allergic disease.

- Severe allergic asthma: improves control and reduces exacerbations in patients with high‑dose inhaled corticosteroids who remain symptomatic. - Chronic spontaneous urticaria: decreases hive frequency and severity in adults with inadequate response to H1‑antihistamines. - Nasal polyposis (post‑operative adjunct): helps reduce polyp recurrence after sinus surgery in selected patients. - Allergic bronchopulmonary aspergillosis (ABPA): adjunctive therapy to reduce IgE‑driven inflammation. - Severe atopic dermatitis: provides symptom relief when conventional therapies have failed. - Food allergy desensitization (off‑label):

Omnycyl        ...  …  …  ... …  ...  … … … …  …  …

Common   g   ...  ... ... ... ... ... ... ... ... ... … ... ... ...

-  ...  ... ... ... ... ... ... …  t  ....  ....  ....  .... -  … "  …  …  ...

This         …  ...